Trial Profile
An association of genetic polymorphisms with clinical outcomes in patients with refractory metastatic colorectal cancer treated with TAS-102
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Feb 2017
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Regorafenib
- Indications Colorectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 09 Feb 2017 Results published in the Annals of Oncology.
- 11 Aug 2016 New trial record